Estrella Immunopharma (ESLA) Other Operating Expenses (2021 - 2026)
Estrella Immunopharma (ESLA) posted quarterly Other Operating Expenses of -$149114.0 for Q1 2026, down 202.19% year-over-year from $145923.2 in Q1 2025, and down 413.02% quarter-over-quarter from -$29066.0 in Q4 2025.
Estrella Immunopharma (ESLA) Other Operating Expenses (2021 - 2026) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Other Operating Expenses for 6 consecutive years, with -$149114.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Operating Expenses fell 202.19% year-over-year to -$149114.0; the TTM figure through Mar 2026 stood at -$325906.0 (up 14.99% YoY), while the FY2025 annual figure was -$226137.0, down 198.36% from the prior year.
- Other Operating Expenses retreated to -$149114.0 in Q1 2026 per ESLA's latest filing, from -$29066.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $5.1 million in Q1 2023 and bottomed at -$706149.0 in Q4 2023.
- Historically, Other Operating Expenses has averaged $459953.1 across 5 years, with a median of -$44761.0 in 2025.
- Annual changes were most pronounced in 2022 — Other Operating Expenses surged 14642.37% — and 2026, when it slumped 202.19%.
- Estrella Immunopharma's Other Operating Expenses stood at $2.5 million in 2022, then plunged by 128.49% to -$706149.0 in 2023, then surged by 83.4% to -$117228.0 in 2024, then surged by 75.21% to -$29066.0 in 2025, then plunged by 413.02% to -$149114.0 in 2026.
- Business Quant data shows ESLA's Other Operating Expenses at -$149114.0 in Q1 2026, -$29066.0 in Q4 2025, and -$102965.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Estrella Immunopharma | 32.29 Mn | 32.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -45,895.00 |
| Mar 31, 2026 | -149,114.00 |
| Dec 31, 2025 | -29,066.00 |
| Sep 30, 2025 | -102,965.00 |
| Jun 30, 2025 | -44,761.00 |
| Mar 31, 2025 | -49,345.00 |
| Dec 31, 2024 | -117,228.00 |
| Sep 30, 2024 | -125,673.00 |
| Jun 30, 2024 | -91,137.00 |
| Mar 31, 2024 | -37,395.00 |
| Dec 31, 2023 | -706,149.00 |
| Jun 30, 2023 | 291,845.00 |
| Mar 31, 2023 | 5.06 Mn |
| Dec 31, 2022 | 2.48 Mn |
| Jun 30, 2022 | 399,765.00 |
| Mar 31, 2022 | 120,740.00 |
| Dec 31, 2021 | 164,100.00 |
| Sep 30, 2021 | 10,514.00 |
| Jun 30, 2021 | 3,559.00 |
| Mar 31, 2021 | 819.00 |